Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $6.56M | $2.01M | — | — | — | — | — |
| Revenue growth | — | — | — | — | -69.3% | — | — | — | — | — |
| Operating income | -$106M | -$8.26M | -$62.9M | -$48.4M | -$9.59M | -$14.2M | -$38.8M | -$18.6M | -$17.9M | -$9.02M |
| Operating margin | — | — | — | -737.4% | -476.0% | — | — | — | — | — |
| Net income | -$74.9M | -$613K | -$49.0M | -$48.2M | -$9.65M | -$14.2M | -$38.8M | -$18.0M | -$17.5M | -$8.83M |
| Net margin | — | — | — | -733.8% | -479.0% | — | — | — | — | — |
| EPS (diluted) | -$3.30 | -$0.03 | -$1.75 | -$1.51 | -$0.17 | -$0.16 | -$4.77 | -$1.87 | -$1.72 | -$0.78 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$14.7M | -$6.90M | -$8.29M | -$1.56M | -$9.83M | -$12.7M | -$21.4M | -$14.7M | -$16.5M | -$8.19M |
| Capital expenditures | $51.0K | $40.0K | $28.0K | $145K | $240K | $52.0K | $74.0K | $118K | $8.00K | $12.0K |
| Free cash flow | -$14.7M | -$6.94M | -$8.32M | -$1.71M | -$10.1M | -$12.8M | -$21.5M | -$14.8M | -$16.5M | -$8.20M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $3.60M | $748K | — | $7.42M | $33.0M | $58.7M | $37.1M | $26.4M | $9.86M | $7.03M |
| Total assets | $125M | $121M | $68.6M | $28.5M | $54.2M | $79.4M | $40.8M | $31.3M | $13.5M | $9.71M |
| Total liabilities | $22.6M | $16.0M | $1.67M | $2.82M | $1.74M | $1.84M | $1.27M | $4.88M | $3.93M | $3.38M |
| Shareholders' equity | $102M | $105M | $66.9M | $25.7M | $52.5M | $77.5M | $39.6M | $26.4M | $9.52M | $6.33M |
| Retained earnings | -$137M | -$138M | -$187M | -$235M | -$245M | -$259M | -$298M | -$316M | -$333M | -$342M |
| Shares (wtd avg diluted) | 23.5M | 24.1M | 28.0B | 31.9B | 70.4M | 7.36M | 8.14M | 9.65M | 10.2M | 11.3M |
Every figure is extracted from Cocrystal Pharma, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.